Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Windtree Therapeutics Inc
WINT
Healthcare
Biotechnology
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and...
preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:WINT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(282)
•••
whytestocks
X
Post by
whytestocks
on Oct 17, 2024 10:02am
Windtree Announces Expansion of Patents with Issuance of Ist
Breaking News: $WINT Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanWARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Aug 20, 2024 4:17pm
Windtree Therapeutics Reports Second Quarter 2024&
News; $WINT Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business UpdatesWARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 2:57am
Windtree Therapeutics, Inc. (NASDAQ:WINT): Navigating the Ca
https://beyondspx.com/2024/08/02/windtree-therapeutics-inc-nasdaqwint-navigating-the-cardiovascular-landscape-with-innovative-therapies/
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 26, 2024 8:57am
WINT.....cash it in if ya got em
S1 withdrawal yesterday Ca Ching !!!!
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 17, 2023 11:20am
WINT......u wouldn't believe me if I told u
Cheers !
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Apr 17, 2023 11:03am
RE:WINT...... 50 : 1 RS eff today
What a game !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 13, 2023 8:00am
New Press Release - Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 06, 2023 8:00am
New Press Release - Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very HighWARRINGTON, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 28, 2023 8:00am
New Press Release - Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 27, 2023 8:00am
New Press Release - Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 24, 2023 9:44am
WINT .... Now that RS is what I call......
A Shave & a Haircut..............Halted on the drop
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 24, 2023 9:03am
WINT..... I have to mention !!!!!
This is Reverse Split #5 LMFAO
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 24, 2023 8:35am
WINT...... 50 : 1 RS eff today
$0.16 x 50 = $8.00 900,000 shares o/s post RS They did a great job laying everyone out with high priced paper....200 mil shs traded as high as $0.38 Now they will do a P.O....trust me (that's
...more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 22, 2023 3:31pm
WINT......took almost all day but..... it's only
1/2 cent from my target support of $0.24....so now it has to rally or oit's heading lower to $0.21 Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 22, 2023 11:46am
WINT.... well it took awhile but it's now in PB mode ; )
Currently at 29 Support at $0.24 Cheers !
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Why Dozens of Pro Athletes are Paying Attention to this Product
Q Precious & Battery Metals To Resume Diamond Drilling La Corne South Project, Val D'or Quebec
Do you want to stay ahead of the markets? See how DealRoom can help.